Latham Represents Precision BioSciences in US$75 Million Offering of Common Stock, Pre-Funded Warrants, and Warrants

Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS^® platform to develop in vivo gene editing therapies for high unmet need diseases, has announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purchase up to 5,407,500 shares of common stock at a combined price of US$6.14 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 1,400,000 shares of its common stock and accompanying one-half of a warrant to purchase up to 700,000 shares of common stock at a combined price of US$6.139995, which represents the per share offering price for the shares of common stock less the US$0.000005 per share exercise price for each pre-funded warrant. The gross proceeds to Precision from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately US$75 million. The offering is expected to close on or about November 12, 2025, subject to customary closing conditions.

Latham & Watkins LLP represents Precision in the offering with a corporate team led by partners Nathan Ajiashvili and Pete Handrinos, with associates Matt DeSilva, Yulong Li, and Samantha Pannone.